Hongene Biotech introduces its proprietary chemoenzymatic ligation platform as a transformative approach for manufacturing therapeutic oligonucleotides, especially siRNA and long sgRNA.
Key Advantages Over Traditional Solid-Phase Synthesis (SPOS):
- Exceptional Purity: Selectively rejects short fragments and impurities; achieves >95% purity for siRNA, >90% for long RNA.
- Scalability & Flexibility: Batch-mode manufacturing from milligrams to hundreds of kilograms.
- Cost Efficiency: Reduces raw material waste and downstream processing costs.
- Sustainability: Lower environmental impact with reduced reagent use.
Core Ligation Methods:
- Sticky-End Ligation: Ideal for siRNA; >95% purity, broad chemical compatibility.
- Splinted Ligation: For long RNA (e.g., sgRNA, pegRNA); enables precise multi-fragment assembly.
Proven Case Studies:
- Inclisiran (siRNA): 97% purity, no ligation-related impurities.
- Divalent exNA-containing siRNA: 97% purity, supports complex designs.
- 100mer G211 sgRNA: 96.8% purity, suitable for CRISPR applications.
Additional Innovation:
- Thermostable T4 RNA Ligase: Enables high-temperature ligation (up to 52°C), reduces secondary structures, improves selectivity and yield.
(For more enzymatic synthesis details, process parameters, and case data, download the full PDF.)